# Cediranib Versus Placebo Plus Cisplatin/Gemcitabine Chemotherapy for Patients With Advanced Biliary Tract Cancers

> **NCT00939848** · PHASE2,PHASE3 · COMPLETED · sponsor: **University College, London** · enrollment: 124 (actual)

## Conditions studied

- Biliary Tract Neoplasms

## Interventions

- **DRUG:** gemcitabine
- **DRUG:** cisplatin
- **DRUG:** Placebo
- **DRUG:** cisplatin
- **DRUG:** cediranib
- **DRUG:** gemcitabine

## Key facts

- **NCT ID:** NCT00939848
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2012-09
- **Final completion:** 2014-09
- **Target enrollment:** 124 (ACTUAL)
- **Last updated:** 2014-10-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00939848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00939848, "Cediranib Versus Placebo Plus Cisplatin/Gemcitabine Chemotherapy for Patients With Advanced Biliary Tract Cancers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00939848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*